Broccoli seed extract: Genotoxicity and subchronic toxicity studies

- Broccoli, specifically the glucoraphanin content, has been noted to have anti-cancer effects in humans.
- A broccoli seed extract (BSE) containing 13% glucoraphanin was tested for genotoxicity and repeated dose toxicity.
- Negative in the Ames assay and in vivo chromosome aberration and sperm abnormality assays in mice.
- The results of these studies support the safe use of BSE in foods or use as a dietary supplement.

Potential health benefits have been attributed to broccoli consumption. Hence, there is potential for use of broccoli seed extract (BSE) in food or for use as a dietary supplement. To assess the potential safety of a BSE product, three genotoxicity experiments, including an Ames, in vivo mouse micronucleus, and in vivo mouse sperm abnormality assay, were carried out. BSE was subject to an acute oral toxicity test and was evaluated in a 30-day feeding study in rats. BSE showed no mutagenic activity in the Ames assay and no evidence of genotoxic potential in the in vivo assays at doses up to 10 g/kg body weight (bw). The LD50 of BSE in rats was >10 g/kg bw/d. In the 30-day feeding study, in which BSE was administered in the diet to provide doses of 0, 0.3, 1.0, or 3.0 g/kg bw/d, no toxicological significant effects were noted on body weight, body weight gain, organ weights, or on the results of hematological, clinical chemistry and histopathological evaluations. The no-observed-adverse-effect level was considered to be 3.0 g/kg bw/d, the highest dose tested. Collectively, these results support the safe use of BSE as a food ingredient or product.